Abstract
ObjectivesTo reveal a single-center experience with endovascular treatment for splenic artery aneurysm (SAA) and analyze the safety and efficacy of the operation in the long-term follow-up.Materials and MethodsA total of 49 patients with SAAs (21 men, 28 women; mean age, 52.4 ± 11.5 years) were enrolled in this study from July 2010 to December 2020. Baseline and characteristics of SAAs were collected. Parent artery coil embolization or combined with sac coil embolization of SAAs, graft-stent implantation, or bare-stent-assisted coil embolization were performed for the treatment of SAAs. Adverse events and follow-up data were recorded.ResultsThe average diameter of SAAs was 3.3 ± 2.5 cm (range, 1.0–13.6 cm). An individual-tailed modality was conducted for three patients. A 100% technical success rate was achieved. No re-intervention procedure was performed in all patients. No major treatment-related adverse events were observed, and no expansion or rupture of SAAs occurred in the average follow-up period of 57.9 ± 27.3 months (19–125 months).ConclusionEndovascular treatment of SAA, including the individual-tailed therapy for three cases, is safe, effective, and minimally invasive with high technical success rates and satisfactory outcomes during the long-term follow-up period.
Highlights
Splenic artery aneurysm (SAA) is a rare vascular disorder with an incident rate of 0.1–2.0%, which accounts for 50–60% in all visceral aneurysms [1,2,3]
The study continued from July 2010 to December 2020 and consecutively included data from patients with SAA diagnosed by CT angiography or ultrasonography and who received endovascular treatment (EVT) in our center
There were 61 aneurysms in 49 patients with SAA, of which 18, 12, 29, and 2 SAAs were located at the proximal, middle, distal splenic artery, and within spleen parenchyma, respectively
Summary
Splenic artery aneurysm (SAA) is a rare vascular disorder with an incident rate of 0.1–2.0%, which accounts for 50–60% in all visceral aneurysms [1,2,3]. Rupture is the most dangerous complication of SAA, with a mortality of up to 10–25% [4]. Surgery used to be the standard treatment method for SAA, but endovascular management become the first option in recent years for the advantages of minimally invasive, highly successful rates of operation, and fewer complications [5,6,7,8]. The long-term outcomes of patients with SAA who are treated with endovascular treatment (EVT) remain unclear. This study aims to investigate the long-term efficiency and safety of different interventional modalities among 49 patients with SAA in our center during the maximum follow-up period of 125 months. Clinical experience of EVT in some cases was discussed
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
